Hilltop Holdings Inc. Invests $281,000 in argenx SE (NASDAQ:ARGX)

Hilltop Holdings Inc. bought a new stake in argenx SE (NASDAQ:ARGX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 519 shares of the company’s stock, valued at approximately $281,000.

Other institutional investors have also added to or reduced their stakes in the company. Cetera Advisors LLC bought a new stake in shares of argenx in the 1st quarter worth approximately $419,000. GAMMA Investing LLC lifted its position in argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after purchasing an additional 40 shares during the period. Park Avenue Securities LLC boosted its stake in argenx by 7.2% during the second quarter. Park Avenue Securities LLC now owns 1,324 shares of the company’s stock worth $569,000 after buying an additional 89 shares in the last quarter. SG Americas Securities LLC increased its holdings in argenx by 10.4% in the 2nd quarter. SG Americas Securities LLC now owns 2,999 shares of the company’s stock valued at $1,290,000 after buying an additional 283 shares during the period. Finally, Sequoia Financial Advisors LLC raised its stake in shares of argenx by 3.1% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company’s stock valued at $737,000 after buying an additional 52 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Stock Performance

NASDAQ ARGX opened at $623.11 on Friday. The stock has a market capitalization of $37.62 billion, a P/E ratio of -708.08 and a beta of 0.59. argenx SE has a 52 week low of $327.73 and a 52 week high of $630.00. The stock has a fifty day moving average of $574.53 and a 200-day moving average of $506.04.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. During the same period last year, the company earned ($1.25) earnings per share. Equities research analysts forecast that argenx SE will post 2.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. JMP Securities lifted their target price on shares of argenx from $497.00 to $606.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Raymond James reaffirmed a “strong-buy” rating and set a $605.00 price objective on shares of argenx in a report on Thursday, October 10th. Wells Fargo & Company increased their target price on argenx from $547.00 to $639.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. William Blair raised argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. Finally, Wedbush reiterated an “outperform” rating and set a $655.00 price objective on shares of argenx in a research note on Tuesday, December 3rd. Three analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, argenx currently has an average rating of “Moderate Buy” and a consensus target price of $635.42.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.